Clinical Trials Logo

Campylobacter Infection clinical trials

View clinical trials related to Campylobacter Infection.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05500417 Active, not recruiting - Clinical trials for Campylobacter Infection

Safety and Immunogenicity of CJCV2 With and Without ALFQ

Start date: September 13, 2022
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, dose-escalating, outpatient trial in a total of approximately 60 subjects, assigned to 3 cohorts (20 subjects per cohort). Each subject will receive one of three intramuscular (IM) vaccinations, spaced 28 days apart, of Campylobacter jejuni Conjugate Vaccine (CJCV2) with or without a fixed dose of the adjuvant Army Liposome Formulation containing QS-21 (ALFQ)(200 mcg 3D-PHAD, 100 mcg QS-21). Three doses (1 ug, 3 ug and 10 ug) of CJCV2 will be evaluated. The first six participants at each dose will be sentinels and randomized in a 1:1 blinded fashion to receive CJCV2 with or without ALFQ. The primary objective is to evaluate the safety of the three different doses of IM injection of CJCV2 with and without ALFQ. The study hypothesis is that the CJCV2 vaccine alone and CJCV2 with ALFQ adjuvant will be safe and that the CJCV2 alone will be immunogenic, with immunogenicity enhanced through the use of the adjuvant ALFQ.

NCT ID: NCT00859716 Active, not recruiting - Clinical trials for Campylobacter Infection

ACE393-103 Vaccination Challenge Study

ACE393-103VC
Start date: October 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether ACE393 vaccination can protect against Campylobacteriosis in a challenge model.